Table 3 Comparison of demographic and clinical characteristics between skeletal muscle loss and non-skeletal muscle loss groups
Variables | SML (No. = 41) | Non-SML (No. = 61) | P value |
|---|---|---|---|
Observation period, days, median [range] | 632 [153–2902] | 785 [184–3278] | 0.021 |
Age, years, median [range] | 67 [38–89] | 72 [34–88] | 0.231 |
Sex (men/women), n | 30/11 | 40/21 | 0.515 |
BMI in men, kg/m2, median [range] | 23.5 [17.6–32.7] | 23.5 [16.2–33.8] | 0.972 |
BMI in women, kg/m2, median [range] | 22.8 [16.0–34.7] | 23.2 [17.1–37.5] | 0.858 |
ΔL3 SMI in men, %, median [range] | −10.1 [−34.2– −4.7] | −0.8 [−4.3–14.2] | <  0.001 |
ΔL3 SMI in women, %, median [range] | −8.3 [−25.2– −5.3] | 1.4 [−4.5–13.0] | <  0.001 |
Etiology (HBV/HCV/NBNC), n | 4/22/15 | 7/28/26 | 0.744 |
ALT, U/L, median [range] | 47 (10–243) | 37 (9–166) | 0.188 |
Total bilirubin, mg/dL, median [range] | 1.1 [0.4–2.4] | 0.9 [0.5–3.5] | 0.423 |
Albumin, g/dL, median [range] | 3.6 [2.1–4.7] | 3.7 [2.0–4.9] | 0.026 |
Platelet count, ×104/μL, median [range] | 11.9 [3.4–80.9] | 12.1 [2.2–27.1] | 0.453 |
Child-Pugh classification (A/B), n | 27/14 | 41/20 | 1.000 |
AFP, ng/mL, median [range] | 54 [2.0–633,900] | 14 [1.0–40,769] | 0.009 |
TNM stage (I + II/III + IV), n | 12/29 | 21/40 | 0.668 |
Maximum tumor diameter, mm, median [range] | 50 [10–198] | 28 [9–120] | 0.009 |
Number of tumors (solitary/multiple), n | 12/29 | 17/44 | 1.000 |
Treatment sessions between CT exams (1/≥ 2, sessions), n | 24/17 | 35/26 | 1.000 |
mRECIST assessment (non-PD/PD), n | 18/23 | 35/26 | 0.227 |
BCAA supplementation (presence/absence), n | 30/11 | 42/19 | 0.665 |